GlassScriptPhysician profile
Scott J Fowler
NPI 1952563892
$4,763.37
in general payments reported to CMS, 2019-2025
27 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $772 · 2021: $969 · 2022: $912 · 2023: $469 · 2024: $382 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $964.33 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $513.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $513.00 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $464.48 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $392.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $366.76 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.65 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $222.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.84 | 2019-2022 | |
| Pfizer INC. | $136.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $120.26 | 2019-2022 | |
| Allergan, INC. | $97.81 | 2019-2020 | |
| Abbott Laboratories | $88.29 | 2022-2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $67.51 | 2019-2021 | |
| Exact Sciences Corporation | $64.44 | 2023-2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $41.07 | 2020-2021 | |
| Vertiflex, INC. | $32.61 | 2019 | |
| Currax Pharmaceuticals LLC | $30.78 | 2021-2022 | |
| Edwards Lifesciences Corporation | $30.36 | 2023 | |
| Dexcom, INC. | $24.05 | 2024 | Dexcom G6 Transmitter |
| Amag Pharmaceuticals, INC. | $19.61 | 2019 | |
| Seqirus USA INC | $17.82 | 2025 | Fluad, Flucelvax |
| Jazz Pharmaceuticals INC. | $17.34 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.74 | 2022 | |
| Alk-Abello, INC | $15.45 | 2024 | Odactra, Ragwitek, Grastek |
| Merck Sharp & Dohme LLC | $13.95 | 2021 | |
| Shire North American Group INC | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.